

10/591678

AP20 Rec'd PCT/PTO 01 SEP 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Von der Kammer *et al.*

Appl. No.: *To Be Assigned (U.S. National  
Phase of PCT/EP2005/050850; Int'l. Filing  
Date: February 28, 2005)*

Filed: Herewith (September 1, 2006)

For: **Diagnostic and Therapeutic Use of  
MAL2 Gene and Protein for  
Neurodegenerative Diseases**

Confirmation No.: *To Be Assigned*

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 2335.0190000/SRL/PAC

**Authorization to Treat a Reply as Incorporating an  
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**


Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913

Date: 9/1/06

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

578492\_1.DOC